Leukemia, B-cell, Chronic  >>  Gazyva (obinutuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT01414205: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark For CLL
Jun 2013 - Jun 2013: For CLL
Completed
2
80
US
Obinutuzumab, RO5072759; GA101, Corticosteroids
Genentech, Inc.
Lymphocytic Leukemia, Chronic
03/13
03/16
NCT01868893: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Checkmark Presentation of data for stage II CLL11 trial at ASH 2013
Dec 2013 - Dec 2013: Presentation of data for stage II CLL11 trial at ASH 2013
Completed
2
20
US
Obinutuzumab, RO 5072759, GA101, Chlorambucil
Genentech, Inc.
Chronic Lymphocytic Leukemia
01/14
01/14
NCT02345863 / 2014-000569-35: Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Completed
2
66
Europe
Bendamustine, GA101, Obinutuzumab, Ibrutinib
German CLL Study Group, Hoffmann-La Roche, Janssen-Cilag Ltd.
Chronic Lymphocytic Leucemia
08/16
03/19

Download Options